ArticleFrontiers in neurology2025
NINJ1 and MMP9: potential biomarkers for intracranial atherosclerosis plaque vulnerability.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Screening of atherosclerosis diagnostic markers based on lymphangiogenesis-related genes and analysis of immunological characteristics.Journal of cardiothoracic surgery · 2026Article
- RhoA accelerates atherosclerosis progression by interacting with Hspa5.Scientific reports · 2026Article
- The role of matrix metalloproteinase 9 in immune-mediated skin diseases.Frontiers in immunology · 2026Review
- Deciphering the clinical implication of an obesity-related gene signature as the novel biomarker for acute myocardial infarction diagnosis.Scientific reports · 2025Article
- Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.Pharmaceutics · 2025Review
- US-triggered on-demand NO-releasing biomimetic nanoparticle to Remodel endothelial microenvironment for enhancing atherosclerosis-specific gas therapy.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: To utilize high-resolution vessel wall imaging (HR-VWI) to identify the characteristic features of culprit plaques in intracranial atherosclerotic stenosis (ICAS) vessels and evaluate the predictive value of serum nerve injury-induced protein 1 (NINJ1) and matrix metalloproteinase 9 (MMP9) for the vulnerability of intracranial atherosclerotic plaques. Methods: This study included symptomatic intracranial atherosclerotic stenosis (sICAS) patients who underwent high-resolution vessel wall imaging (HR-VWI) and healthy individuals. Patients were divided into non-enhancement/enhancement, moderate/severe stenosis, and positive/negative remodeling groups. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were used to evaluate the predictive value of NINJ1 and MMP9 for plaque enhancement, severe stenosis, and positive remodeling. Results: NINJ1 and MMP9 levels were higher in the plaque enhancement group compared to the non-enhancement group (107.04 vs. 93.49, Conclusion: NINJ1 and MMP9 can serve as independent predictors factors for intracranial atherosclerotic plaque enhancement, severe stenosis, and positive remodeling. NINJ1 and MMP9 have the potential to be serum biomarkers for the vulnerability of intracranial atherosclerotic plaques.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.